Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Conditions
Brief summary
The primary objective of the study is to evaluate the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with mild cognitive impairment due to Alzheimer's Disease (MCI due to AD) also known as prodromal AD. Participants will be randomized to receive placebo or AGB101 (220 mg), once daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire (FAQ).
Interventions
DRUGPlacebo Oral Tablet
Placebo oral tablet
DRUGAGB101 220 mg tablet
220 mg AGB101 active compound
Sponsors
National Institute on Aging (NIA)
AgeneBio
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects between 55 and 85 years old (inclusive) in good general health: 1. Willing and able to consent and participate for the duration of the study 2. Have eighth-grade education or good work history sufficient to exclude mental retardation 3. Have visual and auditory acuity adequate for neuropsychological testing 4. Have proficient fluency of the native local language to participate in all the neuropsychological test assessments 2. Have a study partner who has sufficient contact with the subject to be able to provide assessment of memory changes, who can accompany the subject to all the clinic visits for the duration of each visit, and who is able to provide an independent evaluation of the subject's functioning 3. Have MCI due to AD as defined by all of the following criteria and consistent with the National Institute on Aging-Alzheimer's Association criteria: 1. MMSE scores between 24 and 30 (inclusive; exceptions may be made for subjects with \<8 years of education at the discretion of the sponsor) 2. A memory complaint reported by the subject or his/her study partner 3. Evidence of lower memory performance based on delayed recall in the International Shopping List Test (ISLT) 4. A clinical dementia rating (CDR) score of 0.5 with a memory box score of ≥0.5 5. Essentially preserved activities of daily living 6. Cognitive decline not primarily caused by vascular, traumatic, or medical problems (alternative causes of cognitive decline are ruled out) 4. Permitted medications: 1. With potential pro-cognitive effects, such as cholinesterase inhibitors and memantine, must be at a stable dose for ≥3 months prior to screening and remain stable throughout the study; estrogen replacement therapy, Ginkgo biloba, and vitamin E must be at a stable dose for ≥4 weeks prior to screening and remain stable throughout the study 2. Other psychotropics, such as antidepressants and antipsychotics, must be at a stable dose for ≥3 months prior to screening and remain stable throughout the study 5. Willing and able to undergo imaging procedures: 1. A Positron Emission Tomography (PET) scan with Florbetaben(an 18F isotope diagnostic agent) or documented evidence of an amyloid positive PET scan. The Florbetaben scan performed at baseline must be read by a qualified physician with experience in reading amyloid PET scans, and it should be consistent with the presence of amyloid plaques. 2. Repeated MRI scans (3 Tesla) with no contraindications to MRI. MRI scan results are consistent with the diagnosis of amnestic MCI due to Alzheimer's disease with no clinically significant findings of non-AD pathology that could account for the observed cognitive impairment. 6. Willing to allow collection of blood for apolipoprotein E (ApoE) genotyping.
Exclusion criteria
1. Use of anticonvulsant medications or excluded psychotropic medications within 3 months prior to the baseline visit 2. Participation in a therapeutic clinical study for any medical or psychiatric indications within 3 months (6 months for biologics) of the screening visit, or at any time during the study. Subjects must understand that they may only enroll in this clinical study once; they may not enroll in any other clinical study while participating in the current study, and they may not participate in a clinical study of a drug, biologic, therapeutic device, or medical food, in which the last dose/administration was received within 3 months (6 months for biologics) prior to screening. 3. History of hypersensitivity or lack of tolerability to AGB101 (levetiracetam) 4. Severe renal impairment (creatinine clearance of \<30 mL/minute) or undergoing hemodialysis 5. Any significant neurological disease other than suspected incipient AD, such as Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder (lifetime history; infant febrile seizures are not exclusionary), subdural hematoma, multiple sclerosis, or history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities 6. Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body 7. Diagnosis of major depression or bipolar disorder, as described in the Diagnostic and Statistical Manual of Mental Disorders, 5th Ed (DSM-5), within the past 3 years. Psychotic features, agitation, or behavioral problems within the last 3 months that could lead to difficulty complying with the protocol. Subjects must not have a major depressive disorder or other types of depression that could confound diagnosis of MCI due to AD, or clinical assessments, in the opinion of the investigator. The geriatric depression scale (long form score \>9 suggests depression) results should be reviewed by the investigator to assist in this determination. 8. Modified Hachinski Ischemic Scale (HIS) score \>4 9. History of schizophrenia (DSM-5 criteria) 10. History of alcohol or substance abuse or dependence within the past 3 years (DSM-5 criteria) 11. Any significant systemic illness or unstable medical condition that could lead to difficulty in complying with the protocol requirements. 12. Clinically significant abnormalities in B12 or thyroid function test that might interfere with the study. A low B12 (below normative range for elderly) is exclusionary, unless follow-up labs (homocysteine and methylmalonic acid) indicate that it is not physiologically significant. If the B12 deficiency is treated, subjects may become eligible to participate in the study. 13. Residence in a skilled nursing facility. Individuals in independent living communities, assisted living facilities, residential care facilities, or continuing care communities are eligible provided they engage in a sufficient spectrum of activity to permit assessment of all 6 domains contributing to the CDR-SB. Individuals in these facilities must also have a caregiver who has the ability to observe the subject during the study and can participate in clinical evaluations. 14. Any use of excluded medications (e.g., antiepileptics, certain antidepressants or antipsychotics, antihistamines with anticholinergic properties, opiates) 15. Participation in clinical studies using the ISLT, Behavioral Pattern Separation (BPS-O) task, or the trail making test (A, B) within 1 month of screening 16. Female subjects must not be pregnant, lactating, or of childbearing potential (i.e., they must be 2 years post menopause or surgically sterile)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline | 78 weeks | CDR-SB scores at baseline were subtracted from CDR-SB scores at week 78 to generate the change score from baseline, with a possible total range of -18 to 18. Positive change scores reflect greater impairment on the CDR-SB at week 78, while negative change scores reflect less impairment on the CDR-SB at week 78. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Mini Mental Status Exam (MMSE) Score From Baseline | 78 weeks | MMSE scores at baseline were subtracted from MMSE scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect improved performance on the MMSE at week 78, while negative change scores reflect worsening performance on the MMSE at week 78. |
| Change in Functional Activities Questionnaire (FAQ) Score From Baseline | 78 weeks | FAQ scores at baseline were subtracted from FAQ scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect greater impairment on the FAQ at week 78, while negative change scores reflect less impairment on the FAQ at week 78. |
Countries
Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Placebo Oral Tablet Matching placebo to AGB101 tablet once daily, taken orally, for 78 weeks.
Placebo Oral Tablet: Placebo oral tablet | 83 |
| AGB101 220 mg Tablet Single 220 mg AGB101 tablet once daily, taken orally, for 78 weeks.
AGB101 220 mg tablet: 220 mg AGB101 active compound | 81 |
| Total | 164 |
Baseline characteristics
| Characteristic | AGB101 220 mg Tablet | Total | Placebo Oral Tablet |
|---|---|---|---|
| Age, Continuous | 72.2 years STANDARD_DEVIATION 6.7 | 72.7 years STANDARD_DEVIATION 6.9 | 73.1 years STANDARD_DEVIATION 7 |
| Clinical Dementia Rating-Sum of Boxes (CDR-SB) | 2.7 units on a scale STANDARD_DEVIATION 1 | 2.7 units on a scale STANDARD_DEVIATION 1 | 2.7 units on a scale STANDARD_DEVIATION 1.1 |
| Functional Activities Questionnaire (FAQ) | 7.6 units on a scale STANDARD_DEVIATION 5.5 | 7.3 units on a scale STANDARD_DEVIATION 5.4 | 7.0 units on a scale STANDARD_DEVIATION 5.2 |
| Mini Mental Status Exam (MMSE) | 26.2 units on a scale STANDARD_DEVIATION 2.1 | 26.1 units on a scale STANDARD_DEVIATION 2.1 | 26 units on a scale STANDARD_DEVIATION 2.2 |
| Race (NIH/OMB) American Indian or Alaska Native | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 5 Participants | 7 Participants | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 75 Participants | 156 Participants | 81 Participants |
| Sex: Female, Male Female | 32 Participants | 72 Participants | 40 Participants |
| Sex: Female, Male Male | 49 Participants | 92 Participants | 43 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 83 | 2 / 78 |
| other Total, other adverse events | 49 / 83 | 40 / 78 |
| serious Total, serious adverse events | 10 / 83 | 13 / 78 |
Outcome results
Primary
Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline
CDR-SB scores at baseline were subtracted from CDR-SB scores at week 78 to generate the change score from baseline, with a possible total range of -18 to 18. Positive change scores reflect greater impairment on the CDR-SB at week 78, while negative change scores reflect less impairment on the CDR-SB at week 78.
Time frame: 78 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Oral Tablet | Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline | 1.1 score on a scale | Standard Deviation 2 |
| AGB101 220 mg Tablet | Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) Score From Baseline | .9 score on a scale | Standard Deviation 1.5 |
Secondary
Change in Functional Activities Questionnaire (FAQ) Score From Baseline
FAQ scores at baseline were subtracted from FAQ scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect greater impairment on the FAQ at week 78, while negative change scores reflect less impairment on the FAQ at week 78.
Time frame: 78 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Oral Tablet | Change in Functional Activities Questionnaire (FAQ) Score From Baseline | 3.6 units on a scale | Standard Deviation 6.4 |
| AGB101 220 mg Tablet | Change in Functional Activities Questionnaire (FAQ) Score From Baseline | 4 units on a scale | Standard Deviation 5.3 |
Secondary
Change in Mini Mental Status Exam (MMSE) Score From Baseline
MMSE scores at baseline were subtracted from MMSE scores at week 78 to generate the change score from baseline, with a possible total range of -30 to 30. Positive change scores reflect improved performance on the MMSE at week 78, while negative change scores reflect worsening performance on the MMSE at week 78.
Time frame: 78 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Oral Tablet | Change in Mini Mental Status Exam (MMSE) Score From Baseline | -1.9 units on a scale | Standard Deviation 3.7 |
| AGB101 220 mg Tablet | Change in Mini Mental Status Exam (MMSE) Score From Baseline | -2.2 units on a scale | Standard Deviation 2.8 |